The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

MLA

Visser, Loes E., et al. “The Risk of Overanticoagulation in Patients with Cytochrome P450 CYP2C9*2 or CYP2C9*3 Alleles on Acenocoumarol or Phenprocoumon.” Pharmacogenetics, vol. 14, no. 1, Jan. 2004, pp. 27–33. EBSCOhost, https://doi.org/10.1097/00008571-200401000-00003.

APA

Visser, L. E., van Vliet, M., van Schaik, R. H. N., Kasbergen, A. A. H., De Smet, P. A. G. M., Vulto, A. G., Hofman, A., van Duijn, C. M., & Stricker, B. H. C. (2004). The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics, 14(1), 27–33. https://doi.org/10.1097/00008571-200401000-00003

Chicago

Visser, Loes E, Martin van Vliet, Ron H N van Schaik, A A Harrie Kasbergen, Peter A G M De Smet, Arnold G Vulto, Albert Hofman, Cornelia M van Duijn, and Bruno H Ch Stricker. 2004. “The Risk of Overanticoagulation in Patients with Cytochrome P450 CYP2C9*2 or CYP2C9*3 Alleles on Acenocoumarol or Phenprocoumon.” Pharmacogenetics 14 (1): 27–33. doi:10.1097/00008571-200401000-00003.